Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
133.6 USD | -1.23% | +5.21% | +6.36% |
03/06 | Ascendis Pharma Reports 45% Clinical Response in TransCon IL-2 Phase 1/2 Trial | MT |
03/06 | Ascendis Pharma A/S Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.36% | 775.94Cr | |
+17.06% | 12TCr | |
+13.71% | 11TCr | |
-5.75% | 2.48TCr | |
+1.69% | 2.25TCr | |
-10.09% | 1.83TCr | |
-40.52% | 1.63TCr | |
-14.42% | 1.53TCr | |
+3.19% | 1.41TCr | |
+24.11% | 1.17TCr |
- Stock Market
- Equities
- ASND Stock
- News Ascendis Pharma A/S
- Wedbush Adjusts Ascendis Pharma A/S Price Target to $200 From $192, Maintains Outperform Rating